5922-25-8

Usage

InChI:InChI=1/C19H17N3O3S/c23-19-18(22(24)25)17(15-8-4-5-9-16(15)26-19)21-12-10-20(11-13-21)14-6-2-1-3-7-14/h1-9H,10-13H2

Upstream product

• 122-04-3 4-nitro-benzoyl chloride 
• 106-50-3 1,4-phenylenediamine 
• 62-23-7 4-nitro-benzoic acid 
• 624-18-0 benzene-1,4-diamine hydrochloride 

Downstream Products

• 7621-86-5 6-amino-2-(4'-aminophenyl)-benzimidazole 
• 130135-85-2 bis-1,4-<4-(nicotinamido)benzamido>benzene 
• 2362-26-7 N,N'-(p-phenylene)bis(p-aminobenzamide) 

Relevant academic research and scientific papers

Synthesis method of 2-(4-aminophenyl)-5-aminobenzimidazole

The present invention provides a synthesis method of 2- (4-aminophenyl)-5-aminobenzimidazole, comprising the following steps: step 1, preparation of N,N'-bis (4-nitro - α- chlorinated) phenylmethylene p-phenylenediamine; step 2, using N, N'-bis(4-nitro - α- chloro) phenylmethylene p-phenylenediamine preparation N, N'-bis (4-nitro - α - imino) benzyl p-phenylenediamine; step 3, using N, N'-di (4-nitro - α - imino) benzyl p-phenylenediamine preparation 2- ( Step 4, 2-(4-nitro)phenyl-5-aminobenzimidazole was hydrogenated with a hydrogenation catalyst and hydrogen to give 2-(4-amino)phenyl-4-aminobenzimidazole. The present invention is intended to achieve a low production cost and high safety, less harmful pollutants 2- (4-aminophenyl) -5-aminobenzimidazole synthesis method.

PRODRUGS FOR NITROREDUCTASE BASED CANCER THERAPY- 2: Novel amide/Ntr combinations targeting PC3 cancer cells

The use of nitroreductases (NTR) that catalyze the reduction of nitro compounds by using NAD(P)H in GDEPT (Gene-directed enzyme prodrug therapy) studies which minimize toxicity at healthy cells and increases concentration of drugs at cancer cells is remarkable. Discovery of new prodrug/NTR combinations is necessary to be an alternative to known prodrug candidates such as CB1954, SN23862, PR-104A. For this aim, nitro containing aromatic amides (A1-A23) were designed, synthesized, performed in silico ADMET and molecular docking techniques in this study. Prodrug candidates were studied on reduction potentials with Ssap-NtrB by HPLC system. Also, cyototoxic properties and prodrug ability of these amides were investigated using different cancer cell lines such as Hep3B and PC3. As a result of theoretical and biological studies, combinations of A5, A6 and A20 with Ssap-NtrB can be suggested as potential prodrugs/enzyme combinations at NTR based cancer therapy compared with CB1954/NfsB.